中新网广州9月21日电 (记者 王坚)作为2025年岭南科技创新论坛平行论坛之一，"新质生产力赋能医疗 器械前沿科技与成果转化论坛"(下称"成果转化论坛")20日至21日在广州举行。该论坛面向全国高性能医 疗器械科技创新发展与产学研深度融合发展需求，探讨医工融合与新质生产力赋能背景下高性能医疗器 械领域的最新进展。 目前，我国在医疗器械产业领域，初步建立了完善的产业发展生态链，国产化水平持续向好，国内企业 数量不断增加，产品输出力持续增强。 成果转化论坛上，与会专家学者在专题报告中提到，目前，目前我国创新和高性能医疗研发正步入快车 道，人工智能医疗器械发展非常迅猛。2024年获批的人工智能三类医疗器械产品，直接应用的AI技术 约占1/3。其中，医学影像AI医疗器械获批最多。 论坛现场。广东省科协 供图 其中，清华大学长聘教授、生物医学工程学院执行院长王广志作了"智能化医疗器械创新发展与挑战"专 题报告，剖析了智能化医疗器械的技术瓶颈与突破方向。他认为，AI的快速发展，给高端医疗器械创 新带来了巨大机遇和发展动力。为了更好地发挥智能化医疗器械的潜力，突破现有诊疗路径的瓶颈和禁 区，推动临床多层级的研发应用，需要 ...

Core Viewpoint - The article outlines Suzhou's strategic plan to accelerate the development of the "Artificial Intelligence+" city initiative, aiming to establish a robust AI ecosystem by 2026, including significant investments and talent development [1][2][3]. Group 1: Investment and Funding - Suzhou plans to establish an AI fund cluster exceeding 50 billion yuan by 2026 [1]. - The city aims to achieve 50 key core technology breakthroughs and accumulate over 13,000 high-value patents in the AI sector by the end of 2026 [1]. Group 2: Talent Development - By 2026, Suzhou aims to cultivate 240 leading talents in the AI field and establish 15 various talent training platforms and bases [2]. - The city will enhance its talent introduction, training, evaluation, and incentive mechanisms, focusing on attracting high-level and innovative young talents [2]. Group 3: Enterprise and Industry Growth - Suzhou targets the cultivation of 50 intelligent native enterprises, 15 unicorn companies, and 100 city-level unicorn nurturing enterprises by 2026 [2]. - The city plans to nurture 490 provincial-level specialized and innovative enterprises and 1,200 high-tech enterprises in the AI sector by the end of 2026 [3]. Group 4: Infrastructure and Ecosystem Development - Suzhou will select 20 city-level AI industrial parks and develop 3 benchmark parks and 5 characteristic parks to enhance industrial agglomeration effects [3]. - The city is focused on developing embodied intelligence industries and building a complete industrial chain for intelligent vehicle networking [3].

Core Viewpoint - The article discusses the recently approved "Development Plan for Open Innovation of the Biopharmaceutical Industry Chain in China (Jiangsu) Free Trade Pilot Zone," which aims to enhance the biopharmaceutical industry's innovation capabilities and modernize its supply chain by 2030 [2]. Group 1: Key Tasks and Goals - The plan outlines 7 key areas and 18 specific tasks to promote integrated innovation across the entire biopharmaceutical industry chain [2]. - By 2030, the goal is to achieve rapid growth in the biopharmaceutical industry scale, optimize the innovation ecosystem, significantly enhance the modernization level of the industry chain, and improve the level of openness [2]. Group 2: R&D and Innovation - The plan emphasizes the importance of R&D innovation, focusing on advanced treatment methods such as immune cells, stem cells, and gene therapy, as well as innovative medical devices [3]. - Specific measures include strengthening the application of big data and artificial intelligence in drug design and medical device manufacturing, and supporting clinical research in relevant fields [3]. Group 3: Production and Distribution - The plan proposes pilot projects for segmented production of chemical raw materials and biological products, and reforms in the supervision of imported experimental animals [4]. - It aims to enhance the convenience of customs clearance for medical and research materials, leveraging Jiangsu's strong innovation capabilities and complete industry chain [4]. Group 4: Financial Support and Investment - The plan includes significant financial support measures, allowing qualified biopharmaceutical companies to list on various stock exchanges and issue bonds for financing [5]. - It encourages the establishment of investment funds focused on the biopharmaceutical industry and the issuance of real estate investment trusts (REITs) for eligible projects [5]. Group 5: Data Management - The plan highlights the importance of data management in the biopharmaceutical sector, proposing the development of a negative list for data export in this field [6]. - This initiative aims to facilitate efficient data export processes for companies, which is crucial for the overall development of the biopharmaceutical industry [6].

Core Viewpoint - The "Development Plan for the Open Innovation of the Biopharmaceutical Industry Chain in China (Jiangsu) Free Trade Zone" aims to enhance the biopharmaceutical industry's innovation capabilities and modernize its supply chain by 2030, with a focus on key areas such as large molecule biopharmaceuticals, cell and gene therapy, and innovative medical devices [1][2]. Group 1: Key Tasks and Goals - The plan outlines 18 key tasks across seven areas, including enhancing R&D innovation, improving product approval services, and strengthening supply chain systems [1][2]. - By 2030, the goal is to achieve rapid growth in the biopharmaceutical industry scale, optimize the innovation ecosystem, and significantly improve the level of openness and safety assurance capabilities [1][2]. Group 2: Industry Performance and Contribution - In 2024, Jiangsu's biopharmaceutical cluster is projected to generate revenues of 454.39 billion yuan and a profit of 73.04 billion yuan, accounting for 15.1% and 17.9% of the national totals, respectively, making it the leading province in China [2]. - The biopharmaceutical industry within the Jiangsu Free Trade Zone is expected to contribute approximately half of the province's total biopharmaceutical output [2]. Group 3: R&D and Innovation Measures - The plan emphasizes the application of big data and artificial intelligence in drug target screening, molecular design, and medical device manufacturing [2][3]. - It encourages clinical research in advanced treatment methods such as immunotherapy, stem cell therapy, and gene therapy, while supporting the establishment of national and industry standards [2][3]. Group 4: Production and Regulatory Framework - The plan proposes pilot projects for segmented production of chemical raw materials and biological products, as well as reforms in the supervision of imported experimental animals [3]. - It aims to enhance the convenience of customs clearance for medical and research materials, thereby improving the R&D and production environment for companies [3]. Group 5: Financial Support and Investment - The plan includes measures to support biopharmaceutical companies in listing on various stock exchanges and encourages the establishment of investment funds focused on the biopharmaceutical sector [4]. - It also addresses cross-border data flow issues by proposing a negative list for data export in the biopharmaceutical field, which is crucial for foreign investment [4][5].

Core Viewpoint - The article discusses the "Development Plan for Open Innovation of the Biopharmaceutical Industry Chain in the China (Jiangsu) Pilot Free Trade Zone," which aims to enhance the biopharmaceutical industry's innovation capabilities and modernize its supply chain by 2030 [2]. Group 1: Key Objectives and Tasks - The plan includes 7 key areas and 18 specific tasks focused on integrated innovation across the entire biopharmaceutical industry chain [2]. - By 2030, the goal is to achieve rapid growth in the biopharmaceutical industry scale, optimize the innovation ecosystem, and significantly enhance the modernization level of the industry chain [2]. Group 2: R&D and Innovation - The plan emphasizes the importance of R&D innovation, particularly in advanced treatment methods such as immunotherapy, stem cell therapy, and gene therapy [4]. - It proposes measures to strengthen the application of big data and artificial intelligence in drug design and medical device manufacturing [4]. Group 3: Production and Distribution - The plan suggests exploring pilot projects for segmented production of chemical raw materials and biological products, as well as reforming the regulatory model for imported experimental animals [5]. - It aims to improve the convenience of customs clearance for medical and research materials, leveraging Jiangsu's strengths in biopharmaceutical innovation [5]. Group 4: Financial Support and Investment - The plan highlights the need for enhanced financial support, allowing qualified biopharmaceutical companies to list on various stock exchanges and issue bonds for financing [7]. - It encourages the establishment of investment funds specifically for the biopharmaceutical industry and supports the issuance of real estate investment trusts (REITs) for eligible projects [7]. Group 5: Data Management and Cross-Border Flow - The plan addresses concerns regarding cross-border data flow in the biopharmaceutical sector, proposing the development of a negative list for data export in this field [8]. - The establishment of a public service platform for data export safety is also part of the initiative, which aims to facilitate efficient data management for enterprises [8].

Core Viewpoint - The Jiangsu Free Trade Zone aims to enhance the biopharmaceutical industry through an open innovation development plan, targeting significant growth and modernization by 2030 [4][5]. Group 1: Overall Requirements - The plan is guided by Xi Jinping's thoughts and aims to create a globally influential biopharmaceutical hub in Jiangsu, focusing on high-quality development and safety [4][5]. Group 2: Enhancing R&D Innovation Capabilities - The initiative supports major national science and technology projects in biopharmaceuticals, emphasizing breakthroughs in innovative drugs and high-end medical devices [5][6]. - It promotes the application of big data and artificial intelligence in drug design and medical device manufacturing [5][6]. - The establishment of a national biopharmaceutical technology innovation center in Suzhou is encouraged to facilitate technology transfer and application [6][7]. Group 3: Improving Product Approval Services - The plan aims to optimize drug review services and enhance the approval process for innovative drugs and medical devices [8][9]. - It includes strengthening inspection and testing capabilities for biological products, particularly vaccines [8][9]. Group 4: Building a Biopharmaceutical Production and Distribution System - The initiative focuses on developing advanced manufacturing clusters for biopharmaceuticals and high-end medical devices [9][10]. - It aims to enhance customs facilitation for medical devices entering special regulatory zones [9][10]. Group 5: Enhancing Procurement and Usage Policies - The plan encourages the inclusion of eligible innovative drugs in the national medical insurance catalog and aims to streamline the approval process [10][11]. - It explores the introduction of AI-assisted diagnostic technologies in medical services [10][11]. Group 6: Increasing Support for Key Elements - The initiative proposes a market-oriented evaluation mechanism for talent in the biopharmaceutical sector [11][12]. - It supports financial backing for innovative biopharmaceutical companies through various funding avenues [11][12]. Group 7: Ensuring Safety and Risk Management - The plan emphasizes the importance of safety management in biopharmaceutical production and the need for robust risk assessment mechanisms [13][14]. - It aims to align regulatory capabilities with international standards to enhance drug and medical device oversight [13][14].

Core Viewpoint - The Ministry of Commerce and the Jiangsu Provincial Government have issued a development plan for the biopharmaceutical industry chain in the China (Jiangsu) Free Trade Zone, focusing on innovation and technological advancement in biomedicine and medical devices [1] Group 1: Innovation and Technology - The plan emphasizes the need for technological innovation in biomedicine and medical devices [1] - It supports the implementation of major national scientific projects in the biopharmaceutical sector [1] - The initiative aims to break through key core technologies in innovative drugs and high-end medical devices [1] Group 2: Data and AI Applications - There is a strong focus on the application of big data and artificial intelligence in drug target screening, drug molecular design, and the design and manufacturing of medical devices [1] - The plan encourages enterprises to participate in the formulation of national and industry standards for cell and gene therapy products, AI medical devices, biomedical materials, and in vitro diagnostic reagents [1]

Core Viewpoint - The Ministry of Commerce and the Jiangsu Provincial Government have issued a development plan for the open innovation of the entire biopharmaceutical industry chain in the China (Jiangsu) Pilot Free Trade Zone, focusing on technological innovation in biomedicine and medical devices [1] Group 1: Technological Innovation - The plan emphasizes the need to support the implementation of major national scientific and technological projects in the biopharmaceutical field [1] - It aims to leverage new research organizations to achieve breakthroughs in innovative drugs and key core technologies for high-end medical devices [1] - The application of big data and artificial intelligence in drug target screening, drug molecular design, and medical device design and manufacturing is highlighted [1] Group 2: Standardization and Industry Participation - Companies are encouraged to participate in the formulation of national and industry standards for cell and gene therapy products, artificial intelligence medical devices, biomedical materials, and in vitro diagnostic reagents [1]

Core Viewpoint - The "China (Jiangsu) Free Trade Pilot Zone Biopharmaceutical Industry Chain Open Innovation Development Plan" aims to enhance the biopharmaceutical industry in Jiangsu, focusing on innovation, international competitiveness, and high-quality development by 2030 [5][6]. Group 1: Overall Requirements - The plan is guided by Xi Jinping's thoughts and aims to create a world-class biopharmaceutical industry cluster in Jiangsu, with significant growth in industry scale and modernization by 2030 [6]. - Key areas of focus include breakthroughs in major technologies, especially in large molecule biopharmaceuticals, cell and gene therapy, and innovative medical devices [6]. Group 2: Enhancing R&D Innovation Capability - Support for national major projects in biopharmaceuticals and medical devices, emphasizing the use of big data and AI in drug design and medical device manufacturing [7]. - Establishment of a national biopharmaceutical technology innovation center in Suzhou and promotion of health data management standards [7][8]. - Encouragement of international collaborative research and optimization of clinical trial approval processes for foreign investments [8]. Group 3: Improving Product Approval Services - Optimization of drug review services to prioritize innovative drugs and medical devices, including AI medical service software [9]. - Enhancement of inspection and testing capabilities for biopharmaceuticals, particularly vaccines [9]. Group 4: Building Production and Distribution Systems - Development of advanced manufacturing clusters for biopharmaceuticals and high-end medical devices, including contract research and production services [10]. - Improvement of customs facilitation for medical devices not sold in China [10]. Group 5: Procurement and Usage Policies - Promotion of innovative drugs into the national medical insurance catalog and optimization of the listing process [11]. - Expansion of medical service offerings to include AI-assisted diagnostic technologies [11]. Group 6: Strengthening Support and Guarantee Measures - Implementation of talent evaluation policies tailored to the biopharmaceutical industry and facilitation of work permits for foreign medical professionals [12]. - Financial support for innovative biopharmaceutical companies through various funding mechanisms, including public offerings and investment funds [12][13]. Group 7: Ensuring Safety and Risk Management - Strengthening safety production supervision in the biopharmaceutical sector and enhancing risk management for high-risk products [14]. - Building regulatory capabilities in line with international standards for drug and medical device oversight [14]. Group 8: Collaborative Implementation - Jiangsu Provincial Government is responsible for implementing the plan, with support from various national departments to ensure effective execution [15].

Core Viewpoint - The 15th China Medical Device Supervision International Conference opened in Suzhou, focusing on innovation and regulation in the medical device industry, with significant support from government officials and industry leaders [1][2]. Group 1: Government Support and Initiatives - The National Medical Products Administration (NMPA) has concentrated on key areas such as medical robots, high-end medical imaging, AI medical devices, and new biomaterials, supporting the innovation of high-end medical devices [1]. - In 2023, the NMPA has approved 52 innovative products, bringing the total to 367 approved innovative products to date [1]. - The government aims to implement reforms to promote high-quality development in the pharmaceutical and medical device industries, encouraging global medical device products to debut in China [1]. Group 2: Regional Development and Investment Opportunities - Jiangsu province plans to leverage the conference to explore new paths and models for medical device innovation and regulation, aiming to elevate the industry to a higher level [1]. - The province welcomes global pharmaceutical companies to invest and deepen their presence in Jiangsu, aiming to create a hub for innovation, quality, and openness in the global medical device industry [1]. - Jiangsu will continue to optimize the business environment, focusing on the entire lifecycle of product development, transformation, and project implementation to enhance its reputation as a premier business destination [1].